Meet the team

Bhuvaneish Selvaraj

"Using disruptive technologies anchored around human experimental medicine platforms, we hope to decipher cellular and molecular mechanisms that lead to axon degeneration and the selective vulnerability of motor neurons in amyotrophic lateral sclerosis and translating that knowledge to identify novel therapeutic targets and strategies." Bhuvaneish Selvaraj
UK DRI Emerging Leader

Dr. Bhuvaneish T Selvaraj is an engineering graduate from Anna University, India. He began his scientific research career completing a PhD in the lab of Prof Michael Sendtner at University of Wuerzburg, Germany. In 2014, he moved to University of Edinburgh to undertake his postdoctoral research on human stem cell disease modelling of neurodegenerative diseases. In 2020, Dr Selvaraj was awarded the Chancellor’s fellowship, funded by Anne Rowling Regenerative Neurology Clinic, to undertake a research programme that aims to gain greater understanding of the molecular pathomechanisms leading to selective vulnerability of motor neurons in amyotrophic lateral sclerosis. In 2021, he became an Emerging Leader at the UK DRI, sponsored by Prof Siddharthan Chandran.

1. At a glance

Amyotrophic lateral sclerosis (ALS) , a type of motor neurone disease (MND), is a neurodegenerative disease that affects the brain and nerves, causing weakness that gets worse over time, and is eventually fatal. Dr Selvaraj’s research programme seeks to understand the underlying mechanisms that cause neurons to degenerate in ALS, with a view to identifying new therapeutic targets.

There is increasing evidence to suggest that the disease is caused by multiple factors, and that these affect different parts of brain cells. Therefore, a strategy against ALS needs to consider these multiple factors. Dr Selvaraj’s group has previously shown that dysfunction in a type of receptor in the brain, called a glutamate receptor, contributes to the development of C9ORF72 ALS, a form of familial, or genetic, ALS. How this occurs is not yet well understood, and whether the glutamate receptor dysfunction also occurs in sporadic ALS is currently unknown. This programme aims to investigate these points, and identify genes and pathways involved in glutamate receptor dysfunction that could potentially be targets for therapeutic intervention.

The neuromuscular junction (NMJ) is the point at which nerves connect to skeletal muscle, important for movement. In ALS, changes occur at the NMJ prior to the loss of nerve cells. This programme aims to better understand how NMJs degenerate in ALS, to study how this progresses over time as the disease develops, and to determine how the NMJ is regulated, as this will enable the identification of new therapies for ALS.

2. Scientific goals

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease caused by axonal degeneration and loss of motor neurons. The overall objective of Dr Selvaraj’s research programme is to understand mechanisms of selective vulnerability of motor neuron degeneration in ALS and translating that knowledge to identify novel therapeutic targets and strategies. To address this scientific question, Dr Selvaraj’s team uses human stem cell disease modelling including complex organoids and deeply phenotype and clinically linked patient autopsy samples combining with state-of-the art molecular interrogation tools to undertake mechanistic experiments.

Accumulating evidence suggest that MND is multifactorial, and independent pathomechanisms affecting distinct cellular compartments of motor neurons – soma and axon – leading to motor neuron loss and axon degeneration, respectively, thus a successful neuroprotective strategy in ALS would need to target both. The Selvaraj group has shown that glutamate receptor dysfunction, leading to increased vulnerability to excitotoxicity (a form of neuronal injury caused to excessive glutamatergic stimulation), contributes to disease pathogenesis of C9ORF72 ALS, the commonest form of genetic ALS. However, the molecular mechanism of these dysfunctions is still unclear and whether these dysfunctions are generalisable to sporadic ALS cases – which occurs in 90% of ALS cases, is unknown. Therefore, the aim of this programme of research is to determine 1) mechanistically how C9ORF72 mutation leads to glutamate receptor dysfunction and excitotoxicity, 2) whether glutamate receptor dysfunction is generalisable to sporadic ALS - which causes 90% of ALS cases and how it mechanistically links to TDP43 pathology are observed in ca.97 % of ALS cases this includes genetic form of ALS and sporadic ALS with no known genetic mutations. 3) Finally, to perform genome wide CRISPR screening to identify genes/pathways that regulate glutamate receptor dysfunction which will enable the team to identify a rescue strategy for motor neuron vulnerability to excitotoxicity.

The neuromuscular junction (NMJ) is a chemical synapse between motor neuron and skeletal muscle which is crucial for muscle movement. In ALS, NMJ denervation followed by axonal degeneration is known to precede loss of motor neurons. Noting that human NMJs are distinct to other species both structurally and functionally, Dr Selvaraj’s team have developed a human stem cell-based neuro-muscular organoid model to study NMJ structure and function. They aim to better understand the mechanisms underlying how NMJs degenerate in ALS, to study temporal progression of the disease (MN loss and axon degeneration), determine local molecular factors that regulate NMJ maintenance, as this will enable us to identify novel therapies to limit or stop NMJ degeneration and, thus, slow disease progression in ALS.

3. Team members

Dr Shreya Das Sharma (Postdoctoral Researcher - jointly supervised with Prof Siddharthan Chandran)
Ms Andrea Salzinger (PhD student - jointly supervised with Prof Siddharthan Chandran)
Ms Aine Heffernen (PhD student - jointly supervised with Prof Siddharthan Chandran)

4. Collaborations

Within UK DRI:

  • Prof Dario Alessi – Associate member, UK DRI at Edinburgh; Director - MRC-PPU, Dundee

Beyond UK DRI:

5. Topics

amyotrophic lateral sclerosis, frontotemporal dementia, C9ORF72, TDP43, iPSC

6. Techniques

Human iPSC models, organoids, post-mortem studies, transcriptomics/proteomics, electrophysiology

7. Key publications

Pilotto, F., Schmitz, A., Maharjan, N et al. PolyGA targets the ER stress-adaptive response by impairing GRP75 function at the MAM in C9ORF72-ALS/FTD. Acta Neuropathol 144, 939–966 (2022).

Owen G. James, Bhuvaneish T. Selvaraj, Dario Magnani, Karen Burr, Peter Connick, Samantha K. Barton, Navneet A. Vasistha, David W. Hampton, David Story, Robert Smigiel, Rafal Ploski, Peter J. Brophy, Charles ffrench-Constant, David A. Lyons, and Siddharthan Chandran.

iPSC-derived myelinoids to study myelin biology of humans. Developmental Cell 56, 1346–1358 (2021).

Mehta, A.R., Gregory, J.M., Dando, O. et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol 141, 257–279 (2021).

Prudencio, M. et al. (2020) Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 130(11), pp. 6080–6092.

Zhao, C. et al. (2019) Mutant c9orf72 human ipsc‐derived astrocytes cause non‐cell autonomous motor neuron pathophysiology. Glia, 68(5), pp. 1046–1064. Available at:

Selvaraj, B.T., Livesey, M.R., Zhao, C. et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nat Commun 9, 347 (2018).

8. Lab website

Edinburgh profile
Follow Bhuvaneish on Twitter

Founding funders

Latest tweets from @UKDRI

RT @suvankarpal: Congratulations to the formidable @drarpan100 for winning the ECR platform presentation prize at the #CUREND clinical work…
03 Feb 2023 17:11

RT @DrArpan100: Absolutely super, comprehensive talk by @DrNatalieRyan @drcionucl @UKDRI on her research into familial Alzheimer's dementia…
03 Feb 2023 12:09